Third-quarter GAAP diluted EPS of $0.94; adjusted diluted EPS of $1.30
Reported operating margin of 18.1 percent of sales; adjusted operating margin of 23.0 percent, which reflects a 40 basis point increase
ABBOTT PARK, Ill., Oct. 15, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the third quarter ended Sept. 30, 2025.
Third-quarter sales increased 6.9 percent on a reported basis, 5.5 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales1.
Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.30, which excludes specified items.
Year-to-date sales increased 6.1 percent on a reported basis, 6.4 percent on an organic basis, or 7.7 percent when excluding COVID-19 testing-related sales2.
Abbott reaffirms previously provided full-year 2025 organic sales growth guidance.
Abbott reaffirms the midpoint of previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, reflecting double-digit growth at the midpoint.
In July, Abbott announced it received regulatory approval in Japan for TriClip®, a first of-its-kind, minimally invasive treatment option for patients with tricuspid regurgitation, or a leaky tricuspid heart valve.
In August, Abbott announced it received CE Mark for an expanded indication for the company's Navitor® transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic, severe aortic stenosis who are at low or intermediate risk for open-heart surgery.
In August, at the European Society of Cardiology (ESC) Congress, new treatment guidelines were issued that provide additional support for the use of MitraClip® and TriClip in treating valvular heart disease. These new guidelines were backed by evidence from multiple clinical studies.
"Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance," said Robert B. Ford, chairman and chief executive officer, Abbott. "Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders."
THIRD-QUARTER BUSINESS OVERVIEWManagement believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Third Quarter 2025 Results (3Q25)
Sales 3Q25 ($ in millions)
Total Company
Nutrition
Diagnostics
Established Pharmaceuticals
Medical Devices
U.S.
4,299
888
886
—
2,521
International
7,070
1,265
1,367
1,511
2,927
Total reported
11,369
2,153
2,253
1,511
5,448
% Change vs. 3Q24
U.S.
2.3
(6.5)
(14.1)
n/a
13.8
International
9.9
13.3
(1.0)
7.5
15.6
Total reported
6.9
4.2
(6.6)
7.5
14.8
Impact of foreign exchange
1.4
0.2
1.2
0.4
2.3
Organic
5.5
4.0
(7.8)
7.1
12.5
Impact of COVID-19 testing sales 1
(2.0)
—
(8.2)
—
—
Organic (excluding COVID-19 tests)
7.5
4.0
0.4
7.1
12.5
Organic
U.S.
2.3
(6.5)
(14.1)
n/a
13.8
International
7.6
13.0
(3.1)
7.1
11.3
First Nine Months 2025 Results (9M25)
Sales 9M25 ($ in millions)
Total Company
Nutrition
Diagnostics
EstablishedPharmaceuticals
Medical Devices
U.S.
12,743
2,800
2,568
—
7,363
International
20,126
3,711
3,912
4,154
8,349
Total reported
32,869
6,511
6,480
4,154
15,712
% Change vs. 9M24
U.S.
6.4
1.4
(7.4)
n/a
14.4
International
6.0
5.3
(3.3)
5.8
11.3
Total reported
6.1
3.6
(5.0)
5.8
12.8
Impact of foreign exchange
(0.3)
(0.9)
(0.2)
(1.7)
0.4
Impact of business exit*
—
(0.2)
—
—
—
Organic
6.4
4.7
(4.8)
7.5
12.4
Impact of COVID-19 testing sales 2
(1.3)
—
(5.4)
—
—
Organic (excluding COVID-19 tests)
7.7
4.7
0.6
7.5
12.4
Organic
U.S.
6.5
1.9
(7.4)
n/a
14.4
International
6.4
6.9
(3.0)
7.5
10.7
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.
*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024.
Nutrition
Third Quarter 2025 Results (3Q25)
Sales 3Q25 ($ in millions)
Total
Pediatric
Adult
U.S.
888
520
368
International
1,265
457
808
Total reported
2,153
977
1,176
% Change vs. 3Q24
U.S.
(6.5)
(8.4)
(3.8)
International
13.3
17.9
10.9
Total reported
4.2
2.3
5.8
Impact of foreign exchange
0.2
(0.1)
0.4
Organic
4.0
2.4
5.4
U.S.
(6.5)
(8.4)
(3.8)
International
13.0
18.2
10.2
Worldwide Nutrition sales increased 4.2 percent on a reported basis and 4.0 percent on an organic basis in the third quarter.
Growth in the quarter was led by Adult Nutrition, where sales increased 5.8 percent on a reported basis and 5.4 percent on an organic basis, led by strong growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna®, Abbott's market-leading brand of products designed to meet the nutritional requirements for people with diabetes.
First Nine Months 2025 Results (9M25)
Sales 9M25 ($ in millions)
Total
Pediatric
Adult
U.S.
2,800
1,695
1,105
International
3,711
1,377
2,334
Total reported
6,511
3,072
3,439
% Change vs. 9M24
U.S.
1.4
3.0
(0.9)
International
5.3
—
8.8
Total reported
3.6
1.6
5.5
Impact of foreign exchange
(0.9)
(0.9)
(0.9)
Impact of business exit*
(0.2)
—
(0.4)
Organic
4.7
2.5
6.8
U.S.
1.9
3.0
0.3
International
6.9
1.8
10.2
*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024.
Diagnostics
Third Quarter 2025 Results (3Q25)
Sales 3Q25 ($ in millions)
Total
Core Laboratory
Molecular
Point of Care
Rapid Diagnostics
U.S.
886
366
36
111
373
International
1,367
998
95
47
227
Total reported
2,253
1,364
131
158
600
% Change vs. 3Q24
U.S.
(14.1)
10.4
(1.5)
7.9
(33.5)
International
(1.0)
1.6
4.3
8.9
(14.2)
Total reported
(6.6)
3.8
2.6
8.2
(27.3)
Impact of foreign exchange
1.2
1.6
1.8
0.4
0.4
Organic
(7.8)
2.2
0.8
7.8
(27.7)
U.S.
(14.1)
10.4
(1.5)
7.9
(33.5)
International
(3.1)
(0.6)
1.7
7.7
(15.6)
Global Diagnostics sales decreased 6.6 percent on a reported basis, decreased 7.8 percent on an organic basis, and increased 0.4 percent when excluding COVID-19 testing-related sales1.
COVID-19 testing-related sales were $69 million in the quarter, compared to $265 million in the third quarter of the prior year.
Global Core Laboratory Diagnostics sales increased 3.8 percent on a reported basis and increased 2.2 percent on an organic basis. Growth in the quarter was impacted by challenging market conditions in China, including the impact of volume-based procurement programs.
First Nine Months 2025 Results (9M25)
Sales 9M25 ($ in millions)
Total
Core Laboratory
Molecular
Point of Care
Rapid Diagnostics
U.S.
2,568
1,049
111
315
1,093
International
3,912
2,850
265
133
664
Total reported
6,480
3,899
376
448
1,757
% Change vs. 9M24
U.S.
(7.4)
8.3
(0.5)
2.4
(21.2)
International
(3.3)
(1.0)
(2.7)
(0.1)
(12.9)
Total reported
(5.0)
1.3
(2.0)
1.7
(18.2)
Impact of foreign exchange
(0.2)
(0.3)
—
(0.1)
(0.2)
Organic
(4.8)
1.6
(2.0)
1.8
(18.0)
U.S.
(7.4)
8.3
(0.5)
2.4
(21.2)
International
(3.0)
(0.7)
(2.7)
0.3
(12.4)
Established Pharmaceuticals
Third Quarter 2025 Results (3Q25)
Sales 3Q25 ($ in millions)
Total
Key Emerging Markets
Other
U.S.
—
—
—
International
1,511
1,097
414
Total reported
1,511
1,097
414
% Change vs. 3Q24
U.S.
n/a
n/a
n/a
International
7.5
10.3
0.6
Total reported
7.5
10.3
0.6
Impact of foreign exchange
0.4
(0.8)
3.1
Organic
7.1
11.1
(2.5)
U.S.
n/a
n/a
n/a
International
7.1
11.1
(2.5)
Established Pharmaceuticals sales increased 7.5 percent on a reported basis and 7.1 percent on an organic basis in the third quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 10.3 percent on a reported basis and 11.1 percent on an organic basis, led by double-digit growth in several countries across Asia, Latin America and the Middle East.
First Nine Months 2025 Results (9M25)
Sales 9M25 ($ in millions)
Total
Key Emerging Markets
Other
U.S.
—
—
—
International
4,154
3,121
